

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10588367
	Filing Date		2004-08-18
	First Named Inventor		GARCIA-ECHEVERRIA et al.
	Art Unit		1044 10588367 - GAU. 1624
	Examiner Name		
Attorney Docket Number		32910B-US-PCT	

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3432493		1969-03-11	SHORT et al.	
	2	6235746		2001-05-22	DAVIS et al.	
	3	6593326		2003-07-15	BRADBURY et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	EP1054004	EP	A1	2000-11-22	YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568367
Filing Date		2004-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.	
Art Unit	1044 10568367 - GAU. 1624	
Examiner Name		
Attorney Docket Number	32910B-US-PCT	

2	EP1184376	EP	B1	2005-02-02	YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN	<input type="checkbox"/>
3	WO1997/019065	WO	A1	1997-05-29	CELLTECH THERAPEUTICS LIMITED	<input type="checkbox"/>
4	WO1999/050250	WO	A1	1999-10-07	JANSSEN PHARMACEUTICA N.V.	<input type="checkbox"/>
5	WO2000/012485	WO	A1	2000-03-09	ZENECA LIMITED	<input type="checkbox"/>
6	WO2000/039101	WO	A1	2000-07-06	ASTRAZENECA UK LIMITED	<input type="checkbox"/>
7	WO2001/060816	WO	A1	2001-08-23	AMGEN INC.	<input type="checkbox"/>
8	WO2001/064654	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
9	WO2001/064655	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
10	WO2001/064656	WO	A1	2001-09-07	ASTRAZENECA AB	<input type="checkbox"/>
11	WO2003/018021	WO	A1	2003-03-06	AMGEN INC.	<input type="checkbox"/>
12	WO2003/030909	WO	A1	2003-04-17	BAYER CORPORATION	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568367
Filing Date		2004-08-18
First Named Inventor	GARCIA-ECHEVERRIA et al.	
Art Unit	4844 10568367 - GAU: 1624	
Examiner Name		
Attorney Docket Number	32910B-US-PCT	

13	WO2003/063794	WO	A2	2003-08-07	RIGEL PHARMACEUTICALS, INC.	<input type="checkbox"/>
14	WO2003/066601	WO	A1	2003-08-14	SMITHKLINE BEECHAM CORPORATION	<input type="checkbox"/>
15	WO2003/078404	WO	A1	2003-09-25	NOVARTIS AG	<input type="checkbox"/>
16	WO2003/095448	WO	A1	2003-11-20	BAYER PHARMACEUTICALS CORPORATION	<input type="checkbox"/>
17	WO2004/002954	WO	A1	2004-01-08	YAMANOUCHI PHARMACEUTICAL CO., LTD.	<input type="checkbox"/>
18	WO2004/074244	WO	A2	2004-09-02	SMITHKLINE BEECHAM CORPORATION	<input type="checkbox"/>
19	WO2004/080980	WO	A1	2004-09-23	NOVARTIS AG	<input type="checkbox"/>
20	WO2005/016894	WO	A1	2005-02-24	NOVARTIS AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ^s
	1	GHONEIM, Khadiga M., "Synthesis and Evaluation of Some 2-, 4-, and 2,4- Di-substituted-6-methylpyrimidine Derivatives for Antimicrobial Activity", Journal of the Indian Chemical Society, 1986 Vol. 63 No. 10 p. 914-917.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10568367
	Filing Date	2004-08-18
	First Named Inventor	GARCIA-ECHEVERRIA et al.
	Art Unit	1644 10568367 - GAU: 1624
	Examiner Name	
Attorney Docket Number		329108-US-PCT

2	GHOSH, D., "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", Journal of the Indian Chemical Society, 1981 Vol. 58 No. 5 p. 512-513.	<input type="checkbox"/>
3	GHOSH, D., "2,4-Bis(Arylamino)-5-Methylpyrimidines as Antimicrobial Agents", Journal of Medicinal Chemistry, 1967 Vol. 10 No. 5 p. 974-975.	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button		
EXAMINER SIGNATURE		
Examiner Signature	/Deepak Rao/	Date Considered 01/26/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/